May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Self-Reported Perception of Driving Function After Ranibizumab Therapy in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Author Affiliations & Notes
  • P. H. Win
    Retina Institute of California, Pasadena, California
  • N. M. Bressler
    Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • T. S. Chang
    Retina Institute of California, Pasadena, California
  • J. T. Fine
    Genentech, Inc, So. San Francisco, California
  • C. M. Dolan
    Genentech, Inc, So. San Francisco, California
  • J. Ward
    Genentech, Inc, So. San Francisco, California
  • ANCHOR Research Group
    Retina Institute of California, Pasadena, California
  • Footnotes
    Commercial Relationships  P.H. Win, None; N.M. Bressler, Genetech, F; T.S. Chang, None; J.T. Fine, Genentech, Inc, E; C.M. Dolan, Genentech, Inc, E; J. Ward, Genentech, Inc, E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5578. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. H. Win, N. M. Bressler, T. S. Chang, J. T. Fine, C. M. Dolan, J. Ward, ANCHOR Research Group; Self-Reported Perception of Driving Function After Ranibizumab Therapy in Patients With Neovascular Age-Related Macular Degeneration (AMD). Invest. Ophthalmol. Vis. Sci. 2008;49(13):5578. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To examine the effects of ranibizumab (Lucentis®) on self-reported perception of driving function in patients (pts) with neovascular AMD in ANCHOR, a phase III, randomized, controlled, double-masked trial.

 
Methods:
 

Pts were randomized 1:1:1 to PDT + sham intravitreal injection, ranibizumab 0.3 mg + sham PDT, or ranibizumab 0.5 mg + sham PDT. Ranibizumab (or sham) was given monthly; PDT (or sham) was given at day 0 then quarterly as needed. One eye per pt was treated. Driving status and self-reported perception of driving function were measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25), although not defined a priori as key subscales to assess ranibizumab efficacy. Mean change from baseline in subscale scores at month 12 and 24 were compared between the PDT and 0.5 mg ranibizumab groups. NEI-VFQ-25 subscales are scored 0-100; a positive change represents improved function.

 
Results:
 

At baseline, 59.9% of PDT pts and 65.9% of 0.5 mg ranibizumab pts reported they were still driving. At month 12 and 24, respectively, 52.0% and 48.6% of PDT pts vs. 74.0% and 75.4% of 0.5 mg ranibizumab pts reported they were still driving. Changes in the driving subscale are shown below.ANCHOR: Change in Driving Function Subscale of the NEI VFQ-25 at 12 and 24 months*ranibizumab 0.5 mg vs. PDT, p<0.005  

 
Conclusions:
 

At month 12 and 24, fewer PDT than ranibizumab pts reported they were still driving. Also, perception of driving function decreased more for PDT than ranibizumab pts over 24 months. These results suggest that ranibizumab patients reported better vision-related driving function.

 
Clinical Trial:
 

www.clinicaltrials.gov NCT00061594

 
Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×